AxoGen, Inc. (NASDAQ:AXGN) Shares Acquired by New York State Common Retirement Fund

New York State Common Retirement Fund boosted its position in AxoGen, Inc. (NASDAQ:AXGN) by 63.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 69,629 shares of the medical equipment provider’s stock after buying an additional 27,101 shares during the period. New York State Common Retirement Fund’s holdings in AxoGen were worth $1,147,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Quest Partners LLC grew its holdings in AxoGen by 23,066.7% in the third quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 2,076 shares during the last quarter. R Squared Ltd purchased a new stake in shares of AxoGen in the 4th quarter worth about $30,000. Oppenheimer & Co. Inc. acquired a new stake in AxoGen in the 3rd quarter valued at about $156,000. Quantbot Technologies LP purchased a new position in AxoGen during the 3rd quarter valued at about $165,000. Finally, BNP Paribas Financial Markets raised its position in AxoGen by 238.6% during the third quarter. BNP Paribas Financial Markets now owns 12,284 shares of the medical equipment provider’s stock worth $172,000 after acquiring an additional 8,656 shares during the last quarter. 80.29% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group increased their price target on shares of AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, February 26th.

AxoGen Stock Down 3.6 %

Shares of NASDAQ:AXGN opened at $19.29 on Tuesday. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $855.40 million, a P/E ratio of -60.28 and a beta of 1.00. AxoGen, Inc. has a 52-week low of $5.55 and a 52-week high of $21.00. The stock’s fifty day simple moving average is $17.75 and its 200-day simple moving average is $15.11.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.